<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36445090</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-660X</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of clinical microbiology</Title><ISOAbbreviation>J Clin Microbiol</ISOAbbreviation></Journal><ArticleTitle>Sensitivity of Detection and Variant Typing of SARS-CoV-2 in European Laboratories.</ArticleTitle><Pagination><StartPage>e0126122</StartPage><MedlinePgn>e0126122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e01261-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jcm.01261-22</ELocationID><Abstract><AbstractText>The molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is key for clinical management and surveillance. Funded by the European Centre for Disease Prevention and Control, we conducted an external quality assessment (EQA) on the molecular detection and variant typing of SARS-CoV-2 that included 59 European laboratories in 34 countries. The EQA panel consisted of 12 lyophilized inactivated samples, 10 of which were SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Epsilon, Eta, parental B.1 strain) ranging from 2.5 to 290.0 copies/μL or pooled respiratory viruses (adenovirus, enterovirus, influenza virus A, respiratory syncytial virus, or human coronaviruses 229E and OC43). Of all participants, 72.9% identified the presence of SARS-CoV-2 RNA correctly. In samples containing 25.0 or more genome copies/μL, SARS-CoV-2 was detected by 98.3% of the participating laboratories. Laboratories applying commercial tests scored significantly better (<i>P</i> &lt; 0.0001, Kruskal-Wallis test) than those using in-house assays. Both the molecular detection and the typing of the SARS-CoV-2 variants were associated with the RNA concentrations (<i>P</i> &lt; 0.0001, Kruskal-Wallis test). On average, only 5 out of the 10 samples containing different SARS-CoV-2 variants at different concentrations were correctly typed. The identification of SARS-CoV-2 variants was significantly more successful among EQA participants who combined real-time reverse transcription polymerase chain reaction (RT-PCR)-based assays for mutation detection and high-throughput genomic sequencing than among those who used a single methodological approach (<i>P</i> = 0.0345, Kruskal-Wallis test). Our data highlight the high sensitivity of SARS-CoV-2 detection in expert laboratories as well as the importance of continuous assay development and the benefits of combining different methodologies for accurate SARS-CoV-2 variant typing.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mögling</LastName><ForeName>Ramona</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3990-8329</Identifier><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fischer</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9163-2406</Identifier><AffiliationInfo><Affiliation>Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbolt-Universität zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Stanoeva</LastName><ForeName>Kamelia R</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0000-0002-9518-5102</Identifier><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melidou</LastName><ForeName>Angeliki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida Campos</LastName><ForeName>Angélica C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbolt-Universität zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drosten</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbolt-Universität zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Infection Research (DZIF), associated partner site Charité, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biere</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Robert Koch Institute (RKI)grid.13652.33, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijer</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reusken</LastName><ForeName>Chantal B E M</ForeName><Initials>CBEM</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environmentgrid.31147.30 (RIVM), Bilthoven, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drexler</LastName><ForeName>Jan Felix</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-3509-0232</Identifier><AffiliationInfo><Affiliation>Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbolt-Universität zu Berlin, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Infection Research (DZIF), associated partner site Charité, Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Microbiol</MedlineTA><NlmUniqueID>7505564</NlmUniqueID><ISSNLinking>0095-1137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007753" MajorTopicYN="N">Laboratories</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">external quality assessment</Keyword><Keyword MajorTopicYN="N">molecular diagnostics</Keyword><Keyword MajorTopicYN="N">variants</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>29</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36445090</ArticleId><ArticleId IdType="pmc">PMC9769866</ArticleId><ArticleId IdType="doi">10.1128/jcm.01261-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard [Internet]. World Health Organization. 2022. Available from: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, Munday JD, Kucharski AJ, Edmunds WJ, Funk S, Eggo RM, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group . 2020. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 8:e488–e96. 10.1016/S2214-109X(20)30074-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30074-7</ArticleId><ArticleId IdType="pmc">PMC7097845</ArticleId><ArticleId IdType="pubmed">32119825</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra S, Mindermann S, Sharma M, Whittaker C, Mellan TA, Wilton T, Klapsa D, Mate R, Fritzsche M, Zambon M, Ahuja J, Howes A, Miscouridou X, Nason GP, Ratmann O, Semenova E, Leech G, Sandkühler JF, Rogers-Smith C, Vollmer M, Unwin HJT, Gal Y, Chand M, Gandy A, Martin J, Volz E, Ferguson NM, Bhatt S, Brauner JM, Flaxman S, COVID-19 Genomics UK (COG-UK) Consortium . 2021. Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England. EClinicalMedicine 39:101064. 10.1016/j.eclinm.2021.101064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101064</ArticleId><ArticleId IdType="pmc">PMC8349999</ArticleId><ArticleId IdType="pubmed">34401689</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim SSA, Karim QA. 2021. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 398:2126–2128. 10.1016/S0140-6736(21)02758-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02758-6</ArticleId><ArticleId IdType="pmc">PMC8640673</ArticleId><ArticleId IdType="pubmed">34871545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer C, Mögling R, Melidou A, Kühne A, Oliveira-Filho EF, Wolff T, Reiche J, Broberg E, Drosten C, Meijer A, Leitmeyer K, Drexler JF, Reusken CBEM. 2021. Variable sensitivity of SARS-CoV-2 molecular detection in European expert laboratories: external quality assessment, June and July 2020. J Clin Microbiol 59. 10.1128/JCM.02676-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02676-20</ArticleId><ArticleId IdType="pmc">PMC8106723</ArticleId><ArticleId IdType="pubmed">33298612</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerging Viral Diseases-Expert Laboratory Network (EVD-LabNet)
[Available from: https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/evd-labnet.</Citation></Reference><Reference><Citation>Sander A-L, Yadouleton A, de Oliveira Filho EF, Tchibozo C, Hounkanrin G, Badou Y, Adewumi P, René KK, Ange D, Sourakatou S, Sedjro E, Aïssi MAJ, Fidelia H, Djingarey MH, Nagel M, Jo WK, Moreira-Soto A, Drosten C, Landt O, Corman VM, Hounkpatin B, Drexler JF. 2021. Mutations associated with SARS-CoV-2 variants of concern, Benin, early 2021. Emerg Infect Dis 27:2889–2903. 10.3201/eid2711.211353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2711.211353</ArticleId><ArticleId IdType="pmc">PMC8544961</ArticleId><ArticleId IdType="pubmed">34463240</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al.. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>JRC. EURM-019 single stranded RNA (ssRNA) fragments of SARS-CoV-2
Available from: https://crm.jrc.ec.europa.eu/p/EURM-019.</Citation></Reference><Reference><Citation>Fischer C, Pedroso C, Mendrone A, Jr, Bispo de Filippis AM, Vallinoto ACR, Ribeiro BM, et al.. 2018. External quality assessment for Zika virus molecular diagnostic testing. Brazil Emerg Infect Dis 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5938781</ArticleId><ArticleId IdType="pubmed">29470164</ArticleId></ArticleIdList></Reference><Reference><Citation>Iglói Z, Leven M, Abdel-Karem Abou-Nouar Z, Weller B, Matheeussen V, Coppens J, Koopmans M, Molenkamp R. 2020. Comparison of commercial realtime reverse transcription PCR assays for the detection of SARS-CoV-2. J Clin Virol 129:104510. 10.1016/j.jcv.2020.104510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104510</ArticleId><ArticleId IdType="pmc">PMC7833356</ArticleId><ArticleId IdType="pubmed">32570045</ArticleId></ArticleIdList></Reference><Reference><Citation>Thi Nhu Thao T, Labroussaa F, Ebert N, V'kovski P, Stalder H, Portmann J, Kelly J, Steiner S, Holwerda M, Kratzel A, Gultom M, Schmied K, Laloli L, Hüsser L, Wider M, Pfaender S, Hirt D, Cippà V, Crespo-Pomar S, Schröder S, Muth D, Niemeyer D, Corman VM, Müller MA, Drosten C, Dijkman R, Jores J, Thiel V. 2020. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582:561–565. 10.1038/s41586-020-2294-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2294-9</ArticleId><ArticleId IdType="pubmed">32365353</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladimeji P, Pickford J. 2020. Letter of concern re: “Comparison of seven commercial RT-PCR diagnostic kits for COVID-19” van Kasteren et al., Journal of Clinical Virology. J Clin Virol 130:104536. 10.1016/j.jcv.2020.104536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104536</ArticleId><ArticleId IdType="pmc">PMC7336925</ArticleId><ArticleId IdType="pubmed">32745967</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegner F, Roloff T, Huber M, Cordey S, Ramette A, Gerth Y, Bertelli C, Stange M, Seth-Smith HMB, Mari A, Leuzinger K, Cerutti L, Harshman K, Xenarios I, Le Mercier P, Bittel P, Neuenschwander S, Opota O, Fuchs J, Panning M, Michel C, Hallin M, Demuyser T, De Mendonca R, Savelkoul P, Dingemans J, van der Veer B, Boers SA, Claas ECJ, Coolen JPM, Melchers WJG, Gunell M, Kallonen T, Vuorinen T, Hakanen AJ, Bernhoff E, Hetland MAK, Golan Berman H, Adar S, Moran-Gilad J, Wolf DG, Leib SL, Nolte O, Kaiser L, Schmutz S, Kufner V, Zaheri M, Trkola A, Aamot HV, Hirsch HH, et al. 2022. External quality assessment of SARS-CoV-2-sequencing: an ESGMD-SSM pilot trial across 15 European laboratories. J Clin Microbiol 60JCM0169821. 10.1128/JCM.01698-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01698-21</ArticleId><ArticleId IdType="pmc">PMC8769736</ArticleId><ArticleId IdType="pubmed">34757834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacot D, Pillonel T, Greub G, Bertelli C. 2021. Assessment of SARS-CoV-2 genome sequencing: quality criteria and low-frequency variants. J Clin Microbiol 59:e0094421. 10.1128/JCM.00944-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00944-21</ArticleId><ArticleId IdType="pmc">PMC8451431</ArticleId><ArticleId IdType="pubmed">34319802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubik S, Marques AC, Xing X, Silvery J, Bertelli C, De Maio F, et al.. 2021. Recommendations for accurate genotyping of SARS-CoV-2 using amplicon-based sequencing of clinical samples. Clin Microbiol Infect 27:1036 e1–e8. 10.1016/j.cmi.2021.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.03.029</ArticleId><ArticleId IdType="pmc">PMC8016543</ArticleId><ArticleId IdType="pubmed">33813118</ArticleId></ArticleIdList></Reference><Reference><Citation>PAHO. Guidance for SARS-CoV-2 samples selection for genomic characterization and surveillance. Pan American Health Organization; 2021. Feburary 1st.</Citation></Reference><Reference><Citation>Rockett RJ, Arnott A, Lam C, Sadsad R, Timms V, Gray K-A, Eden J-S, Chang S, Gall M, Draper J, Sim EM, Bachmann NL, Carter I, Basile K, Byun R, O'Sullivan MV, Chen SC-A, Maddocks S, Sorrell TC, Dwyer DE, Holmes EC, Kok J, Prokopenko M, Sintchenko V. 2020. Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling. Nat Med 26:1398–1404. 10.1038/s41591-020-1000-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1000-7</ArticleId><ArticleId IdType="pubmed">32647358</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Peacock SJ, Robertson DL, COVID-19 Genomics UK (COG-UK) Consortium . 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409–424. 10.1038/s41579-021-00573-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyson L, Hill EM, Moore S, Curran-Sebastian J, Tildesley MJ, Lythgoe KA, House T, Pellis L, Keeling MJ. 2021. Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics. Nat Commun 12:5730. 10.1038/s41467-021-25915-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25915-7</ArticleId><ArticleId IdType="pmc">PMC8484271</ArticleId><ArticleId IdType="pubmed">34593807</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>